lenacapavir, HIV and Gilead

Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already under review by the FDA.
GILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir. Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention as pre-exposure prophylaxis (PrEP).
A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year | After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate,
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor,
Gilead Presents New HIV Treatment And Cure Research Data
Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety in early HIV treatment.
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of
Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Gilead posts early Phase 1 data for once-yearly HIV PrEP therapy
Gilead (NASDAQ:GILD) on Tuesday announced encouraging initial data from an ongoing Phase 1 trial for lenacapavir, an intramuscular injection given as two once-yearly formulations for pre-exposure prophylaxis (PrEP) in HIV prevention.
MIT Technology Review21h
The Download: HIV prevention shots, and fixing a broken sex doll
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
Health and Me on MSN2h
Yearly Jab For HIV Protection Is Now Almost Here
A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
Scientists develop yearly HIV injection: How it could help millions
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...
MIT Technology Review1d
This annual shot might protect against HIV infections
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Hope for HIV prevention: Annual injection completes important safety trial
However, hope may be on the horizon as a radical new drug has potential to be released if it passes all trials. Lenacapavir, ...
Healio2d
How researchers were able to enroll adolescents in landmark HIV trial
Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...
HIV prevention medication ‘could one day be a yearly jab’ – study suggests
HIV prevention medication ‘could one day be a yearly jab’ – study suggests - Yearly doses could reduce barriers people face ...